Sign In
Buy CDTX
$221.38
+0 (+0%)
At Close: Apr 07, 2026
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Above Fifty Day Moving Average – Should You Sell?
03:32am, Saturday, 24'th Jan 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX - Get Free Report) shares crossed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $220.52 and traded as high
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
01:52am, Friday, 09'th Jan 2026
Pharmaceuticals giant, Merck and Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32
3,187 Shares in Cidara Therapeutics, Inc. $CDTX Bought by ANB Bank
03:28am, Wednesday, 07'th Jan 2026
ANB Bank bought a new position in shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) during the undefined quarter, according to its most recent disclosure with the SEC. The fund bought 3,187 shares of
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Recommendation of “Hold” from Analysts
01:30am, Wednesday, 07'th Jan 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the twelve brokerages that are presently covering the company, MarketBeat.com rep
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?
01:44am, Friday, 02'nd Jan 2026
HighVista Strategies initiated a position in Cidara Therapeutics, buying 70,904 shares valued at $6.79 million. The position represents 1.66% of 13F reportable assets under management (AUM).
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Hold” from Brokerages
01:16am, Saturday, 13'th Dec 2025
Shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX - Get Free Report) have received a consensus recommendation of "Hold" from the twelve research firms that are covering the stock, Marketbeat.com repor
3 Potential Mid-Cap Biotech Buyout Targets In 2026
06:22pm, Wednesday, 03'rd Dec 2025
The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday. The sector has bounced back since. However, small biotech stocks
Geode Capital Management LLC Grows Stock Position in Cidara Therapeutics, Inc. $CDTX
04:33am, Monday, 01'st Dec 2025
Geode Capital Management LLC grew its position in shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) by 576.6% during the second quarter, according to its most recent filing with the Securities and Ex
Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their Rights
12:37pm, Friday, 28'th Nov 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Nov. 28, 2025 Halper Sadeh LLC, an investor
HAPPY THANKSGIVING AND ALERT: The M&A Class Action Firm Continues to Investigate the Merger – EXAS, SEE, CDTX, and MRSN
06:14pm, Thursday, 27'th Nov 2025
NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) -- We wish you a Happy Thanksgiving and Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), who has recovere
hVIVO gains validation from Cidara's takeover; broker calls it a "glowing endorsement"
11:17am, Thursday, 27'th Nov 2025
Merck's agreement to acquire Cidara Therapeutics for about $9.2 billion gives hVIVO PLC (AIM:HVO) a moment of reflected glory. Peel Hunt's analysts highlight that Cidara's lead antiviral, CD388, adva
hVIVO hails $9.2 billion Cidara takeover after key trial wins
02:57am, Thursday, 27'th Nov 2025
hVIVO PLC (AIM:HVO) has praised its long-running partner Cidara Therapeutics after the American biotech agreed to be bought by MSD in a deal worth about $9.2 billion, saying the takeover highlights
Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need for additional enrollment during Southern Hemisphere flu
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-NUVSF, NDTAF, THS, and CDTX
05:30pm, Friday, 21'st Nov 2025
NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders a
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer
09:48am, Thursday, 20'th Nov 2025
Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way
